Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.48 |
| ▸ | MMP3 | P08254 | 2/20 | 0.48 |
| ▸ | MMP13 | P45452 | 2/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MMP12 | P39900 | 1/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8254010 | 0.92 | ADAMTS4 (0.48) | ADAMTS4MMP3MMP13MMP8MMP12 | |
| SCHEMBL8255831 | 0.92 | MMP13 (0.48) | ADAMTS4MMP3MMP13MMP8MMP12 | |
| SCHEMBL8247094 | 0.92 | ADAMTS4 (0.49) | ADAMTS4MMP3MMP13MMP8MMP12 | |
| SCHEMBL10165785 | 0.91 | ADAMTS4 (0.46) | ADAMTS4MMP3MMP13MMP8MMP12 | |
| SCHEMBL8252158 | 0.89 | ADAMTS4 (0.47) | ADAMTS4MMP3MMP13MMP8MMP12 | |
| SCHEMBL8253102 | 0.89 | MMP13 (0.56) | ADAMTS4MMP3MMP13MMP8MMP12 | |
| SCHEMBL8253146 | 0.89 | MMP13 (0.51) | ADAMTS4MMP3MMP13MMP8MMP12 | |
| SCHEMBL8256515 | 0.89 | MMP13 (0.52) | ADAMTS4MMP3MMP13MMP8MMP12 | |
| SCHEMBL8253103 | 0.89 | ADAMTS4 (0.51) | ADAMTS4MMP3MMP13MMP8MMP12 | |
| SCHEMBL8252163 | 0.89 | ADAMTS4 (0.62) | ADAMTS4MMP3MMP13MMP8MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | ADAMTS4 38/4885MMP3 3/4885MMP13 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.